InQpharm’s leading carbohydrate blocker, Glucosanol™, is the first and only medical device carbohydrate blocker for weight management currently in the European market. Launched in 2009, this new innovation from InQpharm is now sold in over 20 markets and is the market leading medical device carbohydrate blocker in Europe.
Approved for general weight management, prevention and treatment of obesity, Glucosanol™ has successfully grown the weight management sector in the European markets where it has been introduced alongside our fat-binding product Liposinol™. In addition, sales of the first market introduction continued to grow after the second product was introduced.
Glucosanol™ stick sachet, launched in Germany this year, is another new innovation which is ready to eat, without water, and available in Cherry and Prune flavours. These small discreet stick sachets suit today’s busy lifestyles and provide a convenient alternative for managing weight loss while on the go.
Certified as a Class IIa medical device, Glucosanol™ reduces the calorie absorption from dietary carbohydrates and helps manage blood glucose levels. It is specially formulated with a proprietary ingredient, PhaseLite™, which is clinically proven to block up to two-thirds of the carbohydrate in a standard meal containing 600 calories.
Glucosanol™ is certified and manufactured according to the stringent EN ISO 13485 for medical devices. The mechanical carbohydrate-blocking action is the scientific basis for Glucosanol’s™ medical device licence in accordance with (MDD/93/42/EEC) for general weight management, prevention and treatment of obesity. This offers new and unique business opportunities with product claims approved in the EU.
This product is part of the BMIsmart™ range of weight management products tailored to help individuals achieve their own desired weight with a healthy Body Mass Index (BMI). Read about our other BMIsmart™ products, Appecal™, Liposinol™ and Zenoctil™.